BofA Securities analyst Jason Gerberry maintains $Alkermes (ALKS.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 46.9% and a total average return of 2.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
A revision in the biotech sector's comparative analysis has led to the expectation of a higher valuation multiple, which has influenced the updated outlook on Alkermes. In anticipation of new data in the year 2025, there is a particular interest in the Phase 2 updates concerning narcolepsy treatments from Alkermes and Centessa.
The firm's revised outlook on Alkermes is based on an updated forecast and a sum-of-the-parts analysis. The focus of investor discussions is increasingly turning to ALKS 2680, due to its prospects of significantly impacting the $10 billion branded narcolepsy and idiopathic hypersomnia markets, particularly as the Phase 2 results are anticipated in the second half of 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美银证券分析师Jason Gerberry维持$阿尔凯默斯 (ALKS.US)$持有评级。
根据TipRanks数据显示，该分析师近一年总胜率为46.9%，总平均回报率为2.8%。
此外，综合报道，$阿尔凯默斯 (ALKS.US)$近期主要分析师观点如下：
生物技术行业比较分析的修订导致人们对更高的估值倍数的预期，这影响了Alkermes的最新前景。预计2025年会有新的数据，因此人们对Alkermes和Centessa关于发作性睡病治疗的第二阶段更新特别感兴趣。
该公司对Alkermes的修订展望基于最新的预测和各部分的总和分析。投资者讨论的焦点越来越多地转向ALKS 2680，因为ALKS 2680有可能对价值100亿美元的品牌发作性睡病和特发性睡眠过度市场产生重大影响，尤其是在预计2025年下半年公布第二阶段结果的情况下。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
